Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: Jun 22, 2012

NEW YORK – University of Massachusetts Medical School researcher Victor Ambros and Massachusetts General Hospital investigator Gary Ruvkun have received the 2012 Dr. Paul Janssen Award for Biomedical Research for their co-discovery of microRNAs.

Ambros' lab discovered the first miRNA, while Ruvkun's lab independently identified how these small, non-coding RNAs regulate their target mRNA. Johnson & Johnson sponsors the award.


The Jackson Laboratory for Genomic Medicine has hired Yu-Hui Rogers to be site administrator for its planned JAX Genomic Medicine facility in Farmington, Conn., where she will oversee all aspects of operations.

Rogers is a genomics researcher and scientific administrator who most recently was VP of core technology development and services at the J. Craig Venter Institute. At the new Jackson lab Rogers will manage finance, human resources, information technology, facilities, and scientific services.

She will start work at a leased space on the campus of the University of Connecticut Health Center in July. Construction on the genomics research center is scheduled to start at the beginning of 2013.


Response Biomedical's shareholders have re-elected its board of directors and set the number of directors at six, the company said this week. The re-elected directors include Anthony Holler; Joseph Keegan; Clinton Severson; Lewis Shuster; Peter Thompson; and David Wang.


Joseph DiZinno has been appointed senior director of federal programs for IntegenX and will work out of the company's newly opened Washington, D.C.-area office, which will support IntegenX's work with federal agencies.

He joins IntegenX from BAE Systems, where he was technical director of homeland security and law enforcement. Previously, he was at the Federal Bureau of Investigation, where he oversaw all case-working and response units related to domestic and international criminal and terrorist cases. He also currently serves as an adjunct faculty member at George Mason University, where he teaches forensic science.


Douglas Kell has been reappointed as chief executive and deputy chair of the UK Biotechnology and Biological Sciences Research Council, the Minister for Universities and Science David Willetts said this week.

Kell has held the top post at BBSRC since 2008, and before that he was director of the Manchester Centre for Integrative Systems Biology. He also has served as director of research at the Institute of Biological Sciences at the University of Aberystwyth, and he was a founding director of Aber Instruments. His research has included a range of topics including systems biology, analytical chemistry, and biochemical and data modeling.


Integrated Diagnostics announced this week that it has named Norman Hardman president of its new InDi Imaging division.

Hardman is currently non-executive director of Chelsea Therapeutics. He was previously the president and CEO of biotech consulting firm Oxalis Partners. Before that he held senior management positions at companies including Amicus Therapeutics, Enzon Pharmaceuticals, Onyx Pharmaceuticals, and GeneMedicine.

InDi also appointed University of California, Los Angeles professor Michael Phelps to the division as an advisor. The inventor of PET imaging technology, Phelps is the chair of the UCLA Department of Molecular and Medical Pharmacology and director of the Crump Institute for Molecular Imaging.


Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.